Urology Medical Billing and Revenue Cycle Management 

Practices usually arrive with one of these.

Section 3

In-office pathology and lab

Two rules do most of the work. Surgical pathology is billed per separately accessioned specimen, not per core and not per slide. Medicare prostate needle biopsy overrides that entirely: one consolidated code, one unit, any number of cores, since January 2015.

Prostate needle biopsy, plain

Medicare patient, twelve cores: one unit of G0416. Not twelve units of 88305.

G0416 is not a pure cut. Its professional component pays more than a single ordinary unit, so it is a substitution. It is still one unit.

Commercial plans used to accept per-specimen prostate billing more often, sometimes with caps. That gap is closing. At least one large national plan has moved to the consolidated code. Read each policy. Do not assume they match Medicare or that they do not.

Everywhere else

One container, one labelled site, one unit. Two sites poured into one jar is one unit forever. That choice is made in the procedure room. No biller can un-combine it later.

Three billing arrangements

• Own the lab, pathologist in the group reads: global billing is possible if group-practice and supervision rules are met. Needs enough volume to keep a pathologist busy.
• Own the lab, buy the read outside: anti-markup applies.
• Send to a reference lab: the lab bills, or you bill under narrow purchased-service rules.

Anti-markup in one sentence

If you buy the interpretation from a pathologist who does not share your practice, you cannot mark it up. Payment is the lowest of what you paid, what you billed, or the fee schedule amount (42 CFR 414.50).

That is why purchased-read pathology often earns less than the spreadsheet predicted. Upside is capped; compliance work is not.

Common errors: global billing on a purchased read, marking up a purchased interpretation, missing performing-supplier details. Global claims in a purchased-service situation are returned unprocessable, not denied, so they never hit the denial report.

Why you can run ancillaries at all

Physician self-referral law would block referring patients into a service you own. The in-office ancillary services exception is the door for your own lab, pathology, imaging and drugs.

Three tests on every claim: who performed or supervised, where it was done, who billed. All three must hold. It is strict liability. Most failures show up in the group-practice definition, not in the exception text itself.

Stains and molecular

Immunohistochemistry in prostate work is per specimen, with add-ons for extra antibodies. Coverage is local.

It is not reasonable and necessary to stain morphologically negative cores, or a negative or suspicious core when obvious cancer is already present elsewhere in the case. Settlements have targeted staining before the pathologist has reviewed the routine slide. Reflex protocols carry that risk even when no one intended to overuse them.

Urinalysis and CLIA

Urinalysis with microscopy is not waived. It is provider-performed microscopy, needs the matching certificate, and may only be done by a physician or midlevel. Do not put the waived-test modifier on it.

A generic UA order defaults to the automated code without microscopy. Microscopy has to be ordered and documented. Billing the microscopy code against an automated-only order is a known improper-payment pattern. Culture and cytology are non-waived and pull higher certificate tiers.

Is in-office pathology worth running?

Waived UA almost always is: high volume, low load, part of the visit.

In-house anatomic pathology is a different decision. You need a pathologist on staff or under contract, group-practice status, higher CLIA (proficiency testing, inspections), and stain medical-necessity discipline in an active enforcement climate. Low specimen volume plus anti-markup on purchased reads can leave compliance cost above margin.

Our view: waived lab, yes. Full anatomic pathology in house, only at real volume and with counsel.

Section 4

Urodynamics without the full-panel habit

Bill what was done, not the panel you usually order. Several codes depend on others. The recurring error is billing the same set on every patient. That is not underbilling. It is the pattern behind the specialty's heavier enforcement cases.

Dependencies

Intra-abdominal voiding pressure is an add-on. It cannot stand alone and only attaches to the combined studies. It does not take a multiple-procedure modifier.

Uroflowmetry is separate from the pressure-flow study. It is billable only when run on separate equipment. Treating it as "included" is a common mistake in both directions.

Combined studies already include the cystometrogram. Billing the standalone cystometrogram next to them duplicates it.

Patient did not void

Do not code voiding pressure studies, uroflowmetry, the intra-abdominal add-on, or the companion voiding cystourethrogram. Ordered and set up is not performed.

Documentation

Each component performed, recorded by who did it: filling, sensations, EMG, flow, voiding pressure. The interpreting clinician has to record an interpretation that lands on a diagnosis. Data without interpretation supports technical work only.

Why this is bigger than the line item

Urodynamics and same-day billing patterns have produced substantial False Claims Act settlements in urology, including allegations that a diagnostic test rarely used in the specialty was run on nearly every new patient.

These tests are not suspect by nature. A practice that runs the identical panel on every patient will eventually be asked why. The answer has to live in the chart, not in a standing protocol.

Section 5 — free urology tool

Urodynamics component checker

Tick what was actually done, answer three questions. Returns supportable codes, dependency errors, suppression list, and documentation reminders. Categorical only. Nowhere to type patient data. Runs in your browser.

This tool also lives at its own address: /tools/urodynamics-component-checker/.

Section 6

Visit with a same-day procedure

Yes when the evaluation is significant and separately identifiable from the procedure. Modifier 25 goes on the evaluation, never on the procedure. This is the most over-applied modifier in the specialty and the most costly to get wrong.

A second diagnosis helps defense but is not required. The note has to show work that stands on its own above and beyond the procedure.

Diagnostic cystoscopy is a separate-procedure code and is included in therapeutic scopes in the same session. Do not bill both.

Skyline Urology paid $1.85 million in 2019 to settle False Claims Act allegations that modifier 25 was used to unbundle routine same-day evaluations that were not separately billable. A corporate integrity agreement followed. Federal reviews across specialties have found a large share of 25 claims unsupported.

Some groups responded by never billing same-day visits. That hands away legitimate work. Bill it when it is real, document it, and sample your own claims instead of waiting for a request.

The visit-complexity add-on is not reported when 25 is on a same-day evaluation.

Section 7

Drug billing, and why our fee does not sit on it

The arithmetic does not work. Medicare pays most in-office drugs at a thin percentage above average sales price, then sequestration cuts the effective add-on further. Realised margin is thinner still. A percentage billing fee on a large drug claim can consume or exceed what you keep on the vial.

We pull drug pass-through out of the fee base and say so up front.

Nominal ASP-plus is reduced by sequestration on the Medicare-paid share. Beyond that, roughly half of buyers pay above the national ASP average, price increases lag in the file, and sequestration hits the whole payment. As one urologist put it in the trade press, a percentage of a small number is not the same as the same percentage of a very large one.

Example shape, not a quote of your rates: a ten-thousand-dollar drug claim at a six percent fee is six hundred dollars. If your net on that vial is three or four hundred, the fee took the margin and more.

Percentage pricing is fine for most of urology. It is a poor fit for pass-through. A company that charges it without asking about drug mix is charging you more than you make on the drug.

What we do

Fee on professional collections. Pass-through out.

Mechanics we still handle

Unit math on depot agents (wrong units cost money both ways). Administration code with the drug. Wastage modifiers: single-dose claims need JW if you discarded billable units or JZ if you discarded none. Neither means the claim can come back unprocessable. Groups that built one modifier and never the other still walk into that edit.

Section 8

Prostate biopsy procedure coding in 2026

The long-standing single biopsy code (55700) was deleted effective 1 January 2026. It is replaced by a family that separates approach and guidance, with an add-on for additional targeted lesions. Claims for 2026 dates of service on the deleted code deny.

Documentation has to state approach and guidance clearly enough for the coder to pick the right line. Targeted multi-lesion work now has an explicit add-on that did not exist under the old single code. Imaging guidance is built into the new descriptors; separate guidance codes are not stacked the way they once were.

The specialty society has signalled further revision may come. Treat this as a living area. This is the procedure code set. Pathology (section 3) is a different rule and a different unit logic.

Section 9

What else moved money in 2026

Two conversion factors (APM participants and everyone else), both higher than 2025. Efficiency adjustment cuts work values on most non-time-based codes. Newly created codes and time-based drug administration codes were exempted for 2026.

Practice-expense methodology shifts value away from facility toward office. Overall specialty impact is often described as near neutral, but that hides a split: facility professional fees fall; in-office ancillary and procedure work is relatively protected. Keeping appropriate work in the office is rewarded. That supports the ancillary economics in section 3; it does not cancel the compliance questions there.

Section 10

What we handle

Section 11

Outsource or keep a certified coder?

Stable mix, limited ancillaries, a biller who works denials: you may not need us. In-office pathology, urodynamics volume and drug share are where specialty errors live and where a generalist will not know to look.

Section 12

Free 48-hour AR audit

We usually start with pathology coding and the urodynamics component pattern. If the file is clean we say so.

Section 13

Common questions

Section 14

Sources

• CMS, 42 CFR 414.50 (anti-markup)
• CMS, 42 CFR 411.355 (in-office ancillary services exception)
• CMS NCCI Policy Manual, Chapter 10 (G0416 prostate needle pathology)
• CMS Medicare Coverage Database: urodynamics and related articles
• CMS CY2026 Medicare Physician Fee Schedule final rule (CMS-1832-F)
• CMS ASP billing resources: JW and JZ modifier policy
• AUA practice management and coding resources
• DOJ: Skyline Urology $1.85 million settlement (2019)
• OIG corporate integrity agreement materials